IP Library Granted Patent US 9,981,939
Granted Patent B2
US 9,981,939 · App. 14/776,603 · Granted May 29, 2018

Compounds and uses thereof for the modulation of hemoglobin

Inventors: Brian W. Metcalf (South San Francisco, CA); Zhe Li (South San Francisco, CA); Qing Xu (South San Francisco, CA); Stephen L. Gwaltney, II (South San Francisco, CA); Jason R. Harris (South San Francisco, CA); Calvin W. Yee (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D401/04A61K8/4913A61K31/445A61K31/5375C07D211/70C07D213/30C07D213/69C07D227/08C07D257/04C07D401/12C07D401/14C07D405/04C07D405/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,939
App. No.
14/776,603
Granted
May 29, 2018
Kind
B2
Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims (19)

1. A compound selected from:

or

a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or

a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2017
From: CYTOKINETICS, INC.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 042183/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2015
From: METCALF, BRIAN W.; LI, ZHE; XU, QING; GWALTNEY, STEPHEN L., II; HARRIS, JASON R.; YEE, CALVIN W.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 037182/0007 →
Continuity (4)
Continuation In Part 13815770 · Mar 15, 2013
Provisional Application 61905803 · Nov 18, 2013
Provisional Application 61905802 · Nov 18, 2013
Related Publication 20160046613A1 · Feb 18, 2016